AbbVie to Host Second-Quarter 2025 Earnings Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Morgan Stanley on Abbvie (ABBV) Buying Capstan: 'We view this acquisition as an incremental positive'
June 30, 2025 12:48 PM EDTMorgan Stanley analyst Terrance Flynn reiterated an Overweight rating and $250.00 price target on Abbvie (NYSE: ABBV).
The analyst comments "ABBV announced on 6/30 an agreement to acquire Capstan Therapeutics (private), a clinical-stage biotech focused on engineering cells in vivo (such as CAR-T) through RNA... More
